Danaher Corporation $DHR Shares Sold by Granite Investment Partners LLC

Granite Investment Partners LLC cut its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 20.6% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 28,754 shares of the conglomerate's stock after selling 7,478 shares during the period. Granite Investment Partners LLC's holdings in Danaher were worth $5,680,000 at the end of the most recent quarter.

• An AI Play Hiding in Plain Sight: A Look at Johnson Controls

Other institutional investors have also modified their holdings of the company. IFG Advisory LLC increased its position in shares of Danaher by 49.0% during the first quarter. IFG Advisory LLC now owns 2,217 shares of the conglomerate's stock worth $454,000 after purchasing an additional 729 shares in the last quarter. Banco Santander S.A. boosted its position in Danaher by 79.5% during the first quarter. Banco Santander S.A. now owns 15,721 shares of the conglomerate's stock worth $3,223,000 after acquiring an additional 6,964 shares during the last quarter. Liberty Wealth Management LLC purchased a new stake in Danaher during the 1st quarter valued at about $3,494,000. Commonwealth Equity Services LLC lifted its stake in Danaher by 1.9% in the 1st quarter. Commonwealth Equity Services LLC now owns 144,868 shares of the conglomerate's stock worth $29,698,000 after purchasing an additional 2,753 shares in the last quarter. Finally, Earned Wealth Advisors LLC acquired a new position in shares of Danaher during the 1st quarter worth approximately $241,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the sale, the senior vice president owned 2,625 shares of the company's stock, valued at $552,352.50. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Brian W. Ellis sold 21,776 shares of the business's stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company's stock, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,248 shares of company stock worth $6,609,663 in the last quarter. 11.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

• 3 Stocks Offering Strong Value and Stability

Several brokerages have issued reports on DHR. Rothschild Redb cut Danaher from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 8th. TD Cowen upped their price target on Danaher from $250.00 to $260.00 and gave the company a "buy" rating in a research note on Wednesday, October 22nd. Morgan Stanley initiated coverage on shares of Danaher in a report on Monday. They issued an "overweight" rating and a $270.00 price objective on the stock. Wells Fargo & Company reiterated a "positive" rating on shares of Danaher in a research report on Thursday, October 23rd. Finally, Bank of America decreased their price objective on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a report on Monday, September 22nd. Twenty analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Danaher currently has a consensus rating of "Moderate Buy" and an average price target of $245.75.

Get Our Latest Stock Report on DHR

Danaher Trading Down 1.1%

• Agilent Technologies Thrives From the Forever Chemicals Crackdown

Shares of DHR stock opened at $224.21 on Tuesday. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a 50 day moving average price of $212.88 and a 200 day moving average price of $203.55. The stock has a market capitalization of $158.37 billion, a P/E ratio of 46.23, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to analysts' expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm's revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.71 EPS. Equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher's payout ratio is presently 26.39%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

• Five stocks we like better than Danaher
• CD Calculator: Certificate of Deposit Calculator
• Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
• Using the MarketBeat Dividend Tax Calculator
• Congress Beat the Market Again—Here Are the 3 Stocks They Bought
• Insider Trading - What You Need to Know
• Go on a Shopping Spree With 3 Top Retail ETFs

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here